Contract notice: Supply of medicinal products for uhkt - advate
It is based on ADVATE
[Antihaemophilic Factor (Recombinant)], a treatment used by haemophilia A patients globally for almost 15 years.
Comments: Hematology revenues were $935 million in the quarter, up 10% driven by heightened demand for ADVATE
Under the terms of the agreement, Baxter will give Biocad production techniques for the localisation of production stages of the dosage form, packaging and final stages of production of the drug Advate
(antihemophilic factor [recombinant]).
Regenerative medicine sales were driven by increased demand for surgical sealant products, including Floseal and Tisseel, while market adoption of Baxter's advanced recombinant therapy, Advate
, was responsible for much of the recombinant products sales surge.
7-fold increase in half-life compared with Advate
, a commercially available product, in 16 previously treated patients.
The companies said data from a mid-stage trial showed the drug lasts longer in the body than an existing product, Advate
, made by Baxter International Inc.
This performance can be attributed to robust growth from several products, including ADVATE
[Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF-PFM)] and GAMMAGARD LIQUID [Immune Globulin Intravenous (IGIV)], marketed as KIOVIG in the European Union, as well as accelerated growth from other plasma-based therapies and biosurgery products.
Factor product brand names by type Plasma-free Recombinant factor Refacto, Helixate FS, Kogenate FS, VIII Advate
Recombinant Factor VIII Recombinate (PRODUCTS NO LONGER MANUFACTURED: BIOCLATE, HELIXATE, KOGENATE) Plasma-derived Factor VIII Hemofil M, Monarch M, Monoclate P, Alphanate, Humate P, Koate DVI Plasma-Derived von Willebrand- Humate P (may also use Koate DVI containing Factor VIII or Alphanate which contain von Willebrand Factor but are assayed in factor VIII units) Recombinant Factor IX Benefix Plasma-Derived Factor IX Alphanine, Mononine Desmopressin DDAVP, Stimate
The drug, named Advate
, is injected into the bloodstream, allowing the body's own clotting mechanism to work.
5 days for Advate
and the average rate at which rFVIIIFc was cleared from the body was 2.
ADYNOVATE, which is built on the full-length ADVATE
molecule, provides proven prophylaxis with simple, twice-weekly dosing for children and adult patients with hemophilia A, helping to further individualize options for this patient population.